Enoby is paid 74.3% below Prolia
6 biosimilars bill against Prolia (J0897). On average they are paid ↓ 27.3% relative to the reference product per 1 MG in 4Q26.
- Prolia (reference)
- Enoby
- Bildyos
- Stoboclo
- Wyost
- Bosaya
- Conexxence
AfliberceptBevacizumabDenosumabEculizumabEpoetin alfaFilgrastimInfliximabNatalizumabPegfilgrastimRanibizumabRituximabTocilizumabTrastuzumabUstekinumab
All products
| Product | Code | CMS description | Per 1 MG | vs. reference | CMS 8% add-on note | 8 quarters |
|---|---|---|---|---|---|---|
| Prolia | J0897 | Denosumab injection | $29.856 | Reference | – | |
| Enoby | Q5167 | Inj, denosumab-qbde, 1 mg | $7.681 | ↓ 74.3% | Yes | |
| Bildyos | Q5162 | Inj, denosumab-nxxp, 1 mg | $15.336 | ↓ 48.6% | Yes | |
| Stoboclo | Q5157 | Inj, denosumab-bmwo, 1 mg | $24.002 | ↓ 19.6% | Yes | |
| Wyost | Q5136 | Inj. denosumab-bbdz, 1 mg | $26.991 | ↓ 9.6% | Yes | |
| Bosaya | Q5161 | Inj, denosumab-kyqq, 1 mg | $27.509 | ↓ 7.9% | Yes | |
| Conexxence | Q5158 | Inj, denosumab-bnht, 1 mg | $28.702 | ↓ 3.9% | Yes |
Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.